Polymorphisms associated with asthma are inversely related to glioblastoma multiforme

Cancer Research

Volumn 65, Issue 14, 2005, Pages 6459-6465

  Schwartzbaum, Judith ^a,b,c   Ahlborn, Anders ^c   Malmer, Beatrice ^d   Lönn, Stefan ^c   Brookes, Anthony J ^e   Doss, Hani ^a   Debinski, Waldemar ^f   Henriksson, Roger ^d   Feychting, Maria ^c  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BIOLOGICAL MARKER; CYCLOOXYGENASE 2; GLUTAMINE; INTERLEUKIN 13; INTERLEUKIN 4 RECEPTOR; SERINE;

ADAM33 GENE; ADULT; ALLERGIC DISEASE; ARTICLE; ASTHMA; CANCER RISK; CONTROLLED STUDY; ECZEMA; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GLIOBLASTOMA; HAY FEVER; HUMAN; IMMUNE SYSTEM; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADAM PROTEINS; ADULT; ASTHMA; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2; DNA-BINDING PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLIOBLASTOMA; HUMANS; INTERLEUKIN-13; INTERLEUKIN-4 RECEPTOR ALPHA SUBUNIT; MALE; MEMBRANE PROTEINS; METALLOENDOPEPTIDASES; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, CELL SURFACE; STAT6 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS;

EID: 22244483108     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3728     Document Type: Article

References (56)

1. CBTRUS. Statistical report: primary brain tumors in the United States, 1995-1999: Central brain tumor registry of the United States; 2002.
2. Fisher JL, Schwartzbaum JA, Wrensch M, Berger MS. Evaluation of epidemiologic evidence for primary adult brain tumor risk factors using evidence-based medicine. Review of neurological surgery by evidence-based medicine standards. S Karger AG; 2005.
3. Schlehofer B, Blettner M, Becker N, Martinsohn C, Wahlendorf J. Medical risk factors and the development of brain tumors. Cancer 1992;69:2541-7.
4. Schlehofer B, Blettner M, Preston-Martin S, et al. Role of medical history in brain tumour development. Results from the international adult brain tumour study. Int J Cancer 1999;82:155-60.
5. Wiemels JL, Wiencke JK, Sison JD, Miike R, McMillan A, Wrensch M. History of allergies among adults with glioma and controls. Int J Cancer 2002;98:609-15.
6. Brenner AV, Linet MS, Fine HA, et al. History of allergies and autoimmune diseases and risk of brain tumors in adults. Int J Cancer 2002;99:252-9.
7. Schwartzbaum J, Jonsson F, Ahlbom A, et al. Cohort studies of association between self-reported allergic conditions, immune-related diagnoses and glioma and meningioma risk. Int J Cancer 2003;106:423-8.
8. Scheibel RS, Meyers CA, Levin VA. Cognitive dysfunction following surgery for intracerebral glioma: influence of histopathology, lesion location, and treatment. J Neurooncol 1996;30:61-9.
9. Wiemels JL, Wiencke JK, Patoka J, et al. Reduced immunoglobulin E and allergy among adults with glioma compared with controls. Cancer Res 2004;64:8468-73.
10. Decker KG. The common variants/multiple disease hypothesis of common complex genetic disorders. Med Hypotheses 2004;62:309-17.
11. Annesi-Maesano I, Didier A, Klossek M, Chanal I, Moreau D, Bousquet J. The score for allergic rhinitis (SFAR): a simple and valid assessment method in population studies. Allergy 2002;57:107-14.
12. Toren K, Brisman J, Jarvholm B. Asthma and asthma-like symptoms in adults assessed by questionnaires. A literature review. Chest 1993;104:600-8.
13. Rothman K, Greenland S. Modern epidemiology: Lippincott-Raven Publishers; 1998.
14. Howard TD, Koppelman GH, Xu J, et al. Gene-gene interaction in asthma: IL4RA and IL13 in a Dutch population with asthma. Am J Hum Genet 2002;70:230-6.
15. Hoffjan S, Nicolae D, Ober C. Association studies for asthma and atopic diseases: a comprehensive review of the literature. Respir Res 2003;4:14.
16. Heinzmann A, Mao XQ, Akaiwa M, et al. Genetic variants of IL-13 signalling and human asthma and atopy. Hum Mol Genet 2000;9:549-59.
17. Howard TD, Whittaker PA, Zaiman AL, et al. Identification and association of polymorphisms in the interleukin-13 gene with asthma and atopy in a Dutch population. Am J Respir Cell Mol Biol 2001;25:377-84.
18. Holgate ST. The epidemic of allergy and asthma. Nature 1999;402:B2-4.
19. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science 1998;282:2258-61.
20. Liu H, Jacobs BS, Liu J, et al. Interleukin-13 sensitivity and receptor phenorypes of human glial cell lines: non-neoplastic glia and low-grade astrocytoma differ from malignant glioma Cancer Immunol Immunother 2000;49:319-24.
21. Barna BP, Estes M, Pettay J, Iwasaki K, Zhou P, Barnett GH. Human astrocyte growth regulation: interleukin-4 sensitivity and receptor expression. J Neuroimmunol 1995;60:75-81.
22. Van Eerdewegh P, Little RD, Dupuis J, et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature 2002;418:426-30.
23. Werner M, Herbon N, Gohlke H, et al. Asthma is associated with single-nucleotide polymorphisms in ADAM33. Clin Exp Allergy 2004;34:26-31.
24. Howard TD, Postma DS, Jongepier H, et al. Association of a disintegrin and metalloprotease 33 (ADAM 33) gene with asthma in ethnically diverse populations. J Allergy Clin Immunol 2003;112:717-22.
25. Nakada M, Okada Y, Yamashita J. The role of matrix metalloproteinases in glioma invasion. Front Biosci 2003;8:e261-9.
26. Papafili A, Hill MR, Brull DJ, et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Atheroscler Thromb Vasc Biol 2002;22:1631-6.
27. Wynn TA. IL-13 effector functions. Annu Rev Immunol 2003;21:425-56.
28. Mentink-Kane MM, Wynn TA. Opposing roles for IL-13 and IL-13 receptor-α2 in health and disease. Immunol Rev 2004;202:191-202.
29. Saito A, Okazaki H, Sugawara I, Yamamoto K, Takizawa H. Potential action of IL-4 and IL-13 as fibrogenic factors on lung fibroblasts in vitro. Int Arch Allergy Immunol 2003;132:168-76.
30. Sivak-Sears N, Schwartzbaum J, Miike R, Moghadassi M, Wrensch M. Case-control study of non-steroidal antiinflammatory drug use and glioblastoma multiforme. Am J Epidemiol 2004;159:1131-9.
31. Howell WM, Jobs M, Gyllensten U, Brookes AJ. Dynamic allele-specinc hybridisation: a new method for scoring single nucleotide polymorphisms. Nat Biotechnol 1999;17:87-8.
32. Prince JA, Feuk L, Howell WM, et al. Robust and accurate single nucliotide polymorphism genotyping by dynamic allele-specific hybridization (DASH) design. Criteria and assay, validation. Genome Res 2001;11:152-62.
33. Howell WM, Jobs M, Brookes AJ. iFRET: an improved fluorescence system for DNA-melting analysis. Genome Res 2002;12:1401-7.
34. Jobs M, Howell WM, Stromqvist L, Mayr T, Brookes AJ. Dash-2: Flexible, low-cost, and high-throughput SNP genotyping by dynamic allele-specinc hybridication on membrane arrays. Genome Res 2003;13:916-24.
35. Sawyer SL, Howell WM, Brookes AJ. Scoring insertion-deletion polymorphisms by dynamic allele-specific hybridization. Biotechniques 2003;35:292-6, 298.
36. Fredman D, Jobs M, Stromqvist L, Brookes AJ. DFold: PCR design that minimizes secondary structure and optimizes downstream genotyping applications. Hum Mutat 2004;24:1-8.
37. Jobs M, Howell WM, Brookes AJ. Creating assays by centrifugation. Biotechniques 2002;32:1322-229.
38. Sawaya R, Ramo OJ. Systemic and thromboembolic effects of meningiomas. In: Al-Mefty O, editor. Meningiomas. New York: Raven Press, Ltd.; 1991. p. 137-44.
39. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434-42.
40. Abbas AK, Lichtman AH, Pober JS. Cellular and molecular immunology. London: W.B. Saunders Company; 1997.
41. Vineis P. A self-fulfilling prophecy: are we under-estimating the role of the environment in gene-environment interaction research? Int J Epidemiol 2004;33:945-6.
42. Genentech. Briefing document on safety (BLASTN 1039760/0): Omalizumab (Xolair) for treatment of allergic asthma; 2003.
43. Louis DN. A molecular genetic model of astrocytoma histopathology. Brain Pathol 1997;7:755-64.
44. Saleh M, Davis ID, Wilks AF. The paracrine role of tumor-derived mIL-4 on tumour-associated endothelium. Int J Cancer 1997;72:664-72.
45. Saleh M, Wiegmans A, Malone Q, Stylli SS, Kaye AH. Effect of in situ retroviral interleukin-4 transfer on established intracranial tumors. J Natl Cancer Inst 1999;91:438-45.
46. Volpert OV Fong T, Kock AE, et al. Inhibition of angiogenesis by interleukin 4. J Exp Med 1998;188:1039-46.
47. Shin WH, Lee D-Y, Keun WP, et al. Microglia expressing interleukin-13 undergo cell death and contribute to neuronal survival in vivo. Glia 2004;46:142-52.
48. Debinski W, Gibo D, Mintz A. Epigenetics in high-grade astrocytomas: opportunities for prevention and detection of brain tumors. Ann N Y Acad Sci 2003;983:232-42.
49. Debinski W, Miner R, Leland P, Obiri NI, Puri HK. Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells. J Biol Chem 1996;271:22428-33.
50. Rahaman SO, Sharma P, Harbor PC, Aman MJ, Vogelbaum MA, Haque SJ. IL-13R(α)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells. Cancer Res 2002;62:1103-9.
51. Rahaman SO, Vogelbaum MA. IL-4 potentiates persistent activation of STAT3 in glioblastoma multiforme cells: cause and consequence. Neuro-oncol 2004;6:344.
52. Madhankumar AB, Debinski W. Structural requirements for interleukin 13 to bind to IL13Rα2, a tumor-associated receptor. Neuro-oncol 2004;6:343.
53. Terabe M, Park JM, Berzofsky JA. Role of IL13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol Immunother 2004;53:79-85.
54. Berzofsky JA, Terabe M, Oh S, et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 2004;113:1515-25.
55. Ichinose M, Barnes PJ. Cytokine-directed therapy in asthma. Curr Drug Targets Inflamm Allergy 2004;3:263-9.
56. Kumar RK, Herbert C, Webb DC, Li L, Foster PS. Effects of anticytokine therapy in a mouse model of chronic asthma. Am J Respir Crit Care Med 2004;170:1043-8.